We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.73 | -0.49% | 148.54 | 150.05 | 147.91 | 149.67 | 5,043,334 | 00:50:01 |
From May 2019 to May 2024
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Wednesday said the U.S. Food and Drug Administration approved expanded pediatric use of its inflammatory disease drug Simponi Aria.
The company said the agency approved Simponi Aria for patients two years of age and older for the treatment of active polyarticular juvenile idiopathic arthritis and has extended the drug's active psoriatic arthritis indication for the same patient population.
Simponi Aria was already approved in the U.S. for adults with moderately to severely active rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 30, 2020 09:40 ET (13:40 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
